Influence of Fructooligosaccharide on Pharmacokinetics of Isoflavones in Postmenopausal Women

The objective of the present paper was to determine the influence of fructooligosaccharide (FOS) on the pharmacokinetics of isoflavones in healthy postmenopausal women. The study was a fixed-sequence, two-phase, crossover study. Twelve subjects received a single oral dose of 300 mL of a soy beverage. Blood samples were collected before the dose and at 0.5, 1, 2, 4, 6, 8, 10, 12, 24, and 32 h after the administration of the soy beverage. After a washout period of at least 1 week, subjects were assigned to receive oral doses of FOS, 5 g each time, twice a day (after breakfast and dinner) for 14 days, followed by a single oral dose of the same soy beverage on the next day. Blood samples were then collected at the same time points mentioned previously. Plasma isoflavone concentrations were determined by HPLC. Continuous oral administrations of FOS followed by a single oral administration of soy beverage caused significant increases inCmax, AUC0–32, and AUC0–∞of genistein and AUC0–32of daidzein, comparing to those obtained following a single oral dose of soy beverage alone. Other pharmacokinetic parameters (Tmaxandt1/2of both aglycones and AUC0–∞of daidzein) between both regimens were not significantly different.

Download Full-text

Effects of the Chinese Herbal Formulation (Liu Wei Di Huang Wan) on the Pharmacokinetics of Isoflavones in Postmenopausal Women

BioMed Research International ◽

10.1155/2015/902702 ◽

2015 ◽

Vol 2015 ◽

pp. 1-8 ◽

Cited By ~ 6

Author(s):

Wirin Limopasmanee ◽

Sunee Chansakaow ◽

Noppamas Rojanasthien ◽

Maleeya Manorot ◽

Chaichan Sangdee ◽

...

Keyword(s):

Plasma Concentration ◽

Oral Dose ◽

Single Oral Dose ◽

Postmenopausal Women ◽

Pharmacokinetic Parameters ◽

Soy Milk ◽

Open Label ◽

Fixed Sequence ◽

Time Curve ◽

Oral Doses

A combination of soy isoflavones andLiu Wei Di Huang Wan(LWDHW) is potentially effective for postmenopausal women with intolerable vasomotor episodes who are not suitable candidates for hormonal therapy. The objective of this open-label, three-phase, crossover study was to determine the influence of both single and multiple oral doses of LWDHW on isoflavone pharmacokinetics in healthy postmenopausal women. Eleven subjects were assigned to receive the following regimens in a fixed sequence with washout periods of at least one week: Phase A, a single oral dose of soy milk; Phase B, a single oral dose of soy milk coadministered with LWDHW; and Phase C, multiple oral doses of LWDHW for 14 days followed by a single oral dose of soy milk. Blood samples were collected and mixed withβ-glucuronidase/sulfatase to hydrolyze isoflavone conjugates to their respective aglycones (i.e., daidzein and genistein) and were determined using high performance liquid chromatography. The pharmacokinetic parameters analyzed were maximal plasma concentrationCmax, time to reach peak concentrationTmax, area under the plasma concentration-time curve (AUC), and half-life (t1/2). The results found no statistically significant differences in pharmacokinetic parameters of daidzein and genistein among the three regimens.

Download Full-text

Effect of Short-Course Oral Ciprofloxacin on Isoflavone Pharmacokinetics following Soy Milk Ingestion in Healthy Postmenopausal Women

Evidence-based Complementary and Alternative Medicine ◽

10.1155/2019/7192326 ◽

2019 ◽

Vol 2019 ◽

pp. 1-10

Author(s):

Nathathai Temyingyong ◽

Nut Koonrungsesomboon ◽

Nutthiya Hanprasertpong ◽

Mingkwan Na Takuathung ◽

Supanimit Teekachunhatean

Keyword(s):

Oral Dose ◽

Gut Microbiota ◽

Single Oral Dose ◽

Postmenopausal Women ◽

Plasma Concentrations ◽

Soy Milk ◽

Blood Samples ◽

Short Course ◽

Oral Ciprofloxacin ◽

Milk Ingestion

Soy isoflavones have several potential benefits related to postmenopausal health. Isoflavone glycosides, found predominantly in nonfermented soy products, e.g., soy milk, require conversion by gut microbiota to their respective bioavailable aglycones prior to absorption into portal circulation. Use of short-course oral ciprofloxacin for the treatment of acute uncomplicated cystitis, the incidence of which is increasing among postmenopausal women, might adversely affect gut microbiota. The objective of this one-group pre-post treatment study was to determine the effect of short-course oral ciprofloxacin on isoflavone pharmacokinetics in healthy postmenopausal women. Eleven postmenopausal subjects were assigned to consume a single oral dose of 375 mL UHT soy milk (SOY phase). Blood samples were collected immediately before soy milk ingestion and at specific times for 32 hours after soy milk ingestion. Following a washout period of at least seven days, subjects were assigned to take 250 mg oral ciprofloxacin after breakfast and dinner for three days, followed by a single oral dose of 375 mL UHT soy milk the next day (CIPRO/SOY phase). Blood samples were collected at the same time points as in the SOY phase. Plasma samples were treated withβ-glucuronidase/sulfatase and plasma concentrations of aglycones (genistein and daidzein) were determined using high-performance liquid chromatography.Cmax,AUC0-t, andAUC0-∞of both aglycones andTmaxof genistein obtained from the CIPRO/SOY phase were significantly lower than those obtained from the SOY phase, whileTmaxof daidzein and t1/2of both aglycones in the two phases were not significantly different.

Download Full-text

Effect of Multiple Oral Doses of the Potent CYP3A4 Inhibitor Clarithromycin on the Pharmacokinetics of a Single Oral Dose of Vonoprazan: A Phase I, Open-Label, Sequential Design Study

Clinical Drug Investigation ◽

10.1007/s40261-016-0488-6 ◽

2016 ◽

Vol 37 (3) ◽

pp. 311-316 ◽

Cited By ~ 12

Author(s):

Helen Jenkins ◽

Richard Jenkins ◽

Alain Patat

Keyword(s):

Oral Dose ◽

Phase I ◽

Single Oral Dose ◽

Sequential Design ◽

Cyp3a4 Inhibitor ◽

Design Study ◽

Open Label ◽

Oral Doses

Download Full-text

The pharmacokinetics of clomipramine and desmethylclomipramine in dogs: parameter estimates following a single oral dose and 28 consecutive daily oral doses of clomipramine

Journal of Veterinary Pharmacology and Therapeutics ◽

10.1046/j.1365-2885.1998.00138.x ◽

1998 ◽

Vol 21 (3) ◽

pp. 214-222 ◽

Cited By ~ 21

Author(s):

C.J. HEWSON ◽

P.D. CONLON ◽

U.A. LUESCHER ◽

R.O. BALL

Keyword(s):

Oral Dose ◽

Single Oral Dose ◽

Parameter Estimates ◽

Oral Doses

Download Full-text

Relative Bioavailability and Pharmacokinetic Parameters Following Adminstration of Single Oral Dose (2×150 mg) of Chloroquine Tablet in Healthy Subjects

Drug Development and Industrial Pharmacy ◽

10.3109/03639049509070878 ◽

1995 ◽

Vol 21 (20) ◽

pp. 2393-2402 ◽

Cited By ~ 2

Author(s):

H. Tajecadeh ◽

M. R. Rouini ◽

A. Gharecolchian

Keyword(s):

Oral Dose ◽

Single Oral Dose ◽

Healthy Subjects ◽

Relative Bioavailability ◽

Pharmacokinetic Parameters

Download Full-text

Netupitant/palonosetron (NEPA) for prevention of delayed chemotherapy-induced nausea and vomiting (CINV) in multiple cycles of chemotherapy.

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.29_suppl.211 ◽

2015 ◽

Vol 33 (29_suppl) ◽

pp. 211-211

Author(s):

Lee Steven Schwartzberg ◽

Richard J. Gralla ◽

Kimia Kashef ◽

Hope Rugo

Keyword(s):

Oral Dose ◽

Single Oral Dose ◽

Complete Response ◽

Control Group ◽

Double Blind ◽

Report Data ◽

Multiple Cycles ◽

To Receive ◽

Delayed Phase ◽

Significant Nausea

211 Background: Prevention of CINV in the delayed phase (24-120 h post-chemotherapy) and over multiple cycles of chemotherapy remains a challenge. NEPA, a fixed combination of the NK1 receptor antagonist (RA) netupitant (300 mg) and the 5-HT3 RA palonosetron (PALO; 0.5 mg), has demonstrated efficacy in multiple studies, in both acute and delayed phases, during the first cycle of moderately or highly emetogenic chemotherapy (MEC and HEC, respectively) regimens. Two clinical trials evaluated NEPA over multiple cycles of chemotherapy. We report data for the delayed phase for each cycle. Methods: Both studies were Phase 3, double-blind, active-controlled studies. In study 1 (MEC), patients were randomized 1:1 to receive a single oral dose of NEPA (n = 724) or PALO 0.5 mg (n = 725) on Day 1; following cycle 1, patients could participate in a multi-cycle extension phase. In study 2 (MEC or HEC), patients were randomized 3:1 to receive a single oral dose of NEPA on Day 1 (n = 309) or oral aprepitant (APR) 125 mg plus oral PALO 0.5 mg on Day 1, then APR 80 mg/d on days 2 and 3 of each cycle (n = 103). In both studies, all patients also received dexamethasone. Efficacy endpoints included complete response (CR; no emesis, no rescue medication) and no significant nausea. Results: In both studies, CR rates were consistently numerically higher with NEPA (Study 1 range: 77%-89%; Study 2 range: 83%-93%) than with PALO (Study 1; range: 69%-83%) or APR/PALO (Study 2; range: 78%-88%) in each cycle up to cycle 6 (Table). In both studies, rates of no significant nausea in the NEPA group were similar to or higher than in the control group. NEPA was well tolerated in both studies; treatment-related adverse events included constipation and headache. Conclusions: These studies demonstrate sustained efficacy of NEPA (administered as a single dose on Day 1) across multiple cycles of MEC or HEC for prevention of CINV in the delayed phase. Clinical trial information: 2009-016775-30; 2010-023297-39. [Table: see text]

Download Full-text

Kinetic effects of multiple oral doses of acetaminophen on a single oral dose of lamotrigine

Clinical Pharmacology & Therapeutics ◽

10.1038/clpt.1990.162 ◽

1990 ◽

Vol 48 (4) ◽

pp. 346-355 ◽

Cited By ~ 37

Author(s):

Michelle Depot ◽

J Robert Powell ◽

John A Messenheimer ◽

Gilles Cloutier ◽

Michael J Dalton

Keyword(s):

Oral Dose ◽

Single Oral Dose ◽

Kinetic Effects ◽

Oral Doses

Download Full-text

Mimosine, administered orally, and two related compounds of chemical defleecing agents for sheep

Australian Journal of Agricultural Research ◽

10.1071/ar9781065 ◽

1978 ◽

Vol 29 (5) ◽

pp. 1065 ◽

Cited By ~ 4

Author(s):

PJ Reis ◽

DA Tunks ◽

AM Downes

Keyword(s):

Oral Dose ◽

Single Oral Dose ◽

Intravenous Infusion ◽

Fibre Diameter ◽

Daily Ration ◽

Before And After ◽

Fibre Growth ◽

High Concentrations ◽

Oral Doses ◽

Related Compounds

Oral doses of mimosine (ranging from 400 to 800 mg/kg body weight) were given to 71 sheep, either as two successive daily doses (10 sheep) or as a single dose (61 sheep). The effectiveness of these treatments for defleecing was assessed and in some sheep measurements were made of the concentration of mimosine in plasma after dosing, and of the rate of wool growth before and after dosing. In addition, the effectiveness as defleecing agents of two related compounds (an analogue of mimosine, 'isomimosine', and a metabolite, 3,4-dihydroxypyridine (DHP)) was assessed. Two successive daily doses of mimosine (300 mg/kg/day) allowed all sheep to be defleeced. With sheep consuming a daily ration of 600 g, a single oral dose of mimosine (400 mg/kg) was sufficient to allow defleecing of most sheep; when the daily ration was 1200 g, a dose of 600 mg/kg was required to allow defleecing of most sheep. The effectiveness of oral doses for defleecing could be explained by the absorption of mimosine over a period in excess of 24 hr. Concentrations of mimosine in plasma were usually above 100 µmoles/l 24 hr after an effective dose. Failure to achieve complete cessation of fibre growth occurred occasionally, irrespective of dose level, and two sheep died after dosing. Fasting prior to dosing appeared to obviate the effects of previous high nutrition, but increased the risk of toxic effects. Fasting resulted in exceptionally high concentrations of mimosine in plasma (200–300 µmoles/l) 1 and 2 days after dosing. Both fibre diameter and mass of wool grown were increased in the early regrowth after dosing with mimosine. 'Isomimosine' had a similar potency to mimosine for stopping fibre growth in sheep, whether given as an intravenous infusion or as a single oral dose. DHP, given as an intravenous infusion, was ineffective as a defleecing agent.

Download Full-text